Intra-Cellular Therapies EPS - Earnings per Share 2013-2022 | ITCI
Intra-Cellular Therapies annual and quarterly earnings per share history from 2013 to 2022. Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
- Intra-Cellular Therapies EPS for the quarter ending March 31, 2022 was $-0.78, a 20% increase year-over-year.
- Intra-Cellular Therapies EPS for the twelve months ending March 31, 2022 was $-3.63, a 15.24% increase year-over-year.
- Intra-Cellular Therapies 2021 annual EPS was $-3.5, a 8.36% increase from 2020.
- Intra-Cellular Therapies 2020 annual EPS was $-3.23, a 20.52% increase from 2019.
- Intra-Cellular Therapies 2019 annual EPS was $-2.68, a 5.63% decline from 2018.
| Intra-Cellular Therapies Annual EPS |
| 2021 |
$-3.50 |
| 2020 |
$-3.23 |
| 2019 |
$-2.68 |
| 2018 |
$-2.84 |
| 2017 |
$-2.12 |
| 2016 |
$-2.69 |
| 2015 |
$-2.91 |
| 2014 |
$-1.07 |
| 2013 |
$-1.56 |
| 2012 |
$-2.96 |
| Intra-Cellular Therapies Quarterly EPS |
| 2022-03-31 |
$-0.78 |
| 2021-12-31 |
$-1.05 |
| 2021-09-30 |
$-0.95 |
| 2021-06-30 |
$-0.85 |
| 2021-03-31 |
$-0.65 |
| 2020-12-31 |
$-0.75 |
| 2020-09-30 |
$-0.79 |
| 2020-06-30 |
$-0.96 |
| 2020-03-31 |
$-0.73 |
| 2019-12-31 |
$-0.74 |
| 2019-09-30 |
$-0.63 |
| 2019-06-30 |
$-0.68 |
| 2019-03-31 |
$-0.63 |
| 2018-12-31 |
$-0.75 |
| 2018-09-30 |
$-0.76 |
| 2018-06-30 |
$-0.68 |
| 2018-03-31 |
$-0.65 |
| 2017-12-31 |
$-0.56 |
| 2017-09-30 |
$-0.53 |
| 2017-06-30 |
$-0.41 |
| 2017-03-31 |
$-0.62 |
| 2016-12-31 |
$-0.64 |
| 2016-09-30 |
$-0.70 |
| 2016-06-30 |
$-0.71 |
| 2016-03-31 |
$-0.64 |
| 2015-12-31 |
$-0.67 |
| 2015-09-30 |
$-0.91 |
| 2015-06-30 |
$-0.61 |
| 2015-03-31 |
$-0.72 |
| 2014-12-31 |
$-0.53 |
| 2014-09-30 |
$-0.22 |
| 2014-06-30 |
$-0.15 |
| 2014-03-31 |
$-0.17 |
| 2013-12-31 |
$-0.33 |
| 2013-09-30 |
$-0.28 |
| 2013-06-30 |
$-0.56 |
| 2013-03-31 |
$-0.39 |
| 2012-12-31 |
$0.00 |
| 2012-09-30 |
$-0.40 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$5.539B |
$0.084B |
|
Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York.
|
